Autopsy report · NCT01222572

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

“Slow accrual due to restrictive eligibility criteria”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 10 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Dana-Farber Cancer Institute

Sponsor type

University, hospital or other

Conditions

Non-small Cell Lung Cancer; Lung Cancer; NSCLC

Interventions

Stereotactic boost; Conventional RT; Etoposide; Cisplatin

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• CD8 Reactivity to Microorganisms in Blood and Breast Milk
  “Slow/insufficient accrual” (76% match in meaning)
• Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
  “Slow accrual within enrollment time period: projected accrual goal not achieved.” (73% match in meaning)
• Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure
  “slow accrual; insufficient funding to continue to accrue” (71% match in meaning)
• tDCS and Cognitive Training for Restrictive Eating Disorders
  “Slow accrual/low enrollment” (71% match in meaning)
• Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
  “Slow accrual” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.